These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 10172066)

  • 1. Who uses streptokinase vs alteplase (t-PA), and why?
    Sanchez LA
    Pharmacoeconomics; 1992 Nov; 2(5):428-9. PubMed ID: 10172066
    [No Abstract]   [Full Text] [Related]  

  • 2. Is alteplase (t-PA) more cost-effective than streptokinase?
    Sanchez LA
    Pharmacoeconomics; 1992 Nov; 2(5):427-8. PubMed ID: 10172065
    [No Abstract]   [Full Text] [Related]  

  • 3. Study assigns dollar value to alteplase-streptokinase debate.
    Am J Health Syst Pharm; 1995 Aug; 52(15):1600. PubMed ID: 7583819
    [No Abstract]   [Full Text] [Related]  

  • 4. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.
    Massel D
    Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocardial infarction, thrombolytic therapy, and economics.
    Shander D
    Clin Cardiol; 1993 Nov; 16(11):845. PubMed ID: 8269667
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.
    Woo KS; White HD
    Pharmacoeconomics; 1993 Mar; 3(3):192-204. PubMed ID: 10172049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical decision making in the choice of a thrombolytic agent for acute myocardial infarction. Quebec Acute Coronary Care Working Group.
    Brophy JM; Joseph L; Theroux P
    Med Decis Making; 1999; 19(4):411-8. PubMed ID: 10520679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombolytic treatment. Streptokinase is more economical than alteplase.
    Mucklow JC
    BMJ; 1995 Dec; 311(7018):1506. PubMed ID: 8520368
    [No Abstract]   [Full Text] [Related]  

  • 11. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thrombolytic therapy in acute myocardial infarction].
    Pedersen TR
    Tidsskr Nor Laegeforen; 1994 May; 114(14):1646-7. PubMed ID: 8079271
    [No Abstract]   [Full Text] [Related]  

  • 13. Thrombolytic therapy for acute myocardial infarction.
    Clem JR
    S D J Med; 1994 Jan; 47(1):27-8. PubMed ID: 8122094
    [No Abstract]   [Full Text] [Related]  

  • 14. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardial infarction: A decision analysis.
    Hiatt MD
    Cardiology; 1999; 91(4):243-9. PubMed ID: 10545680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
    GUSTO investigators
    N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incremental cost-effectiveness ratio of alteplase in patients with acute myocardial infarction in the French setting.
    Pelc A; Dardenne J; Frelon JH; Hanania G
    Pharmacoeconomics; 1997 Jun; 11(6):595-605. PubMed ID: 10173031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and comparison of the adverse effects of streptokinase and alteplase.
    Tisdale JE; Colucci RD; Ujhelyi MR; Kluger J; Fieldman A; Chow MS
    Pharmacotherapy; 1992; 12(6):440-4. PubMed ID: 1492007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in the fibrinolytic system components during acute myocardial infarction.
    Ioannidou-Papayannaki E; Lefkos N; Boudonas G; Efthimiadis A; Psirropoulos D; Vogas V; Papadopoulos I; Klonizakis I
    Acta Cardiol; 2000 Aug; 55(4):247-53. PubMed ID: 11041123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.